

Karyn A Goodman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4586567/publications.pdf>

Version: 2024-02-01

198
papers

8,979
citations

61687

45
h-index

54771

88
g-index

200
all docs

200
docs citations

200
times ranked

9302
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1013-1026.	3.2	19
2	SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS374-TPS374.	0.8	15
3	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2556.	0.8	292
4	Anal Cancer: Emerging Standards in a Rare Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 2774-2788.	0.8	13
5	Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer. <i>Hpb</i> , 2021, 23, 1072-1083.	0.1	16
6	Response to, “Role of neoadjuvant radiochemotherapy for esophageal cancers over pre/peri-operative chemotherapy in the era of COVID-19 and beyond” <i>Radiotherapy and Oncology</i> , 2021, 154, e17.	0.3	1
7	Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 989-1000.	2.0	20
8	Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 186-200.	0.4	8
9	Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician. <i>JCO Precision Oncology</i> , 2021, 5, 317-324.	1.5	9
10	Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. <i>Cancer Research</i> , 2021, 81, 3255-3269.	0.4	37
11	Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 614640.	1.3	4
12	Controversies in radiotherapy for pancreas cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1460-1466.	0.8	7
13	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. <i>Pancreas</i> , 2021, 50, 469-493.	0.5	55
14	Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7208-7218.	0.7	6
15	Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 217-226.	0.4	7
16	Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer—Ready for Prime Time?. <i>JAMA Oncology</i> , 2021, 7, 687.	3.4	4
17	Reply to M. Ratain. <i>JCO Precision Oncology</i> , 2021, 5, 937-938.	1.5	0
18	Mature Experiences Using Local Therapy for Oligometastases. <i>Seminars in Radiation Oncology</i> , 2021, 31, 180-185.	1.0	1

#	ARTICLE	IF	CITATIONS
19	A first radiotherapy application of functional bulboclitoris anatomy, a novel female sexual organ-at-risk, and organ-sparing feasibility study. <i>British Journal of Radiology</i> , 2021, 94, 20201139.	1.0	4
20	Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2803-2815.	0.8	58
21	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3773-3777.	0.8	17
22	Tailoring Distress Screening in Oncology Populations: Timing distress screening in surgically resectable esophageal cancer. <i>Oncology Issues</i> , 2021, 36, 30-35.	0.0	0
23	Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2020, 155, 361.	2.2	2
24	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> , 2020, 10, e136-e146.	1.1	41
25	Non-surgical Watch and Wait Approach to Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 118-124.	1.0	0
26	High incidence of prolonged rectal bleeding and advanced stage cancer in early-onset colorectal cancer patients. <i>Colorectal Cancer</i> , 2020, 9, CRC31.	0.8	4
27	Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2677-2694.	0.8	169
28	Hepatocellular Carcinoma in the COVID-19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?. <i>Oncologist</i> , 2020, 25, e1249-e1250.	1.9	9
29	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	3.2	118
30	Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 173-179.	0.6	40
31	Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 148, 194-200.	0.3	43
32	The role of neoadjuvant chemotherapy in elderly patients with borderline or locally advanced pancreatic cancer: Is it safe and feasible?. <i>Journal of Clinical Oncology</i> , 2020, 38, 685-685.	0.8	2
33	Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminary Findings. <i>Tomography</i> , 2020, 6, 261-271.	0.8	10
34	Concurrent versus sequential neoadjuvant chemoradiation therapy for esophageal and gastroesophageal junction adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-395.	0.8	0
35	Analyzing the impact of neoadjuvant radiation dose on pathologic response and survival outcomes in esophageal and gastroesophageal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 712-722.	0.6	7
36	Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. <i>Radiation Oncology</i> , 2019, 14, 114.	1.2	34

#	ARTICLE	IF	CITATIONS
37	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2019, 9, 322-332.	1.1	121
38	Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 591-605.	0.4	5
39	Executive Summary of the American Radium Society Appropriate Use Criteria for Local Excision in Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 977-993.	0.4	6
40	The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. Journal of Gastrointestinal Oncology, 2019, 10, 462-473.	0.6	4
41	When oncologic treatment options outpace the existing evidence: Contributing factors and a path forward. Journal of Cancer Policy, 2019, 20, 100188.	0.6	2
42	Quantifying Allowable Motion to Achieve Safe Dose Escalation in Pancreatic SBRT. Practical Radiation Oncology, 2019, 9, e432-e442.	1.1	6
43	Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e88-e95.	1.8	17
44	Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. Clinical Cancer Research, 2019, 25, 3352-3365.	3.2	18
45	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. Clinical Colorectal Cancer, 2019, 18, 167-174.	1.0	3
46	Positron-Emission Tomography Scan-â€œDirected Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. Journal of Thoracic Oncology, 2019, 14, 540-546.	0.5	15
47	Anal Cancer in the Era of Dose Painted Intensity Modulated Radiation Therapy: Implications for Regional Nodal Therapy. Seminars in Radiation Oncology, 2019, 29, 137-143.	1.0	0
48	Tu1336 COMPARISON OF TRADITIONAL BACK-LOADED FIDUCIAL NEEDLES WITH PRELOADED FIDUCIAL NEEDLES IN EUS-GUIDED FIDUCIAL MARKER PLACEMENT FOR IMAGE-GUIDED RADIATION THERAPY (IGRT) IN PATIENTS WITH PANCREATIC ADENOCARCINOMA (PC): A RANDOMIZED CONTROLLED TRIAL (RCT). Gastrointestinal Endoscopy, 2019, 89, AB577-AB578.	0.5	0
49	The Clinical and Dosimetric Impact of Real-Time Target Tracking in Pancreatic SBRT. International Journal of Radiation Oncology Biology Physics, 2019, 103, 268-275.	0.4	24
50	Improved survival in rectal cancer patients who are treated with long-â€œcourse versus short-â€œcourse neoadjuvant radiotherapy: A propensity-â€œmatched analysis of the NCDB. Journal of Surgical Oncology, 2019, 119, 518-531.	0.8	6
51	Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. Clinical Cancer Research, 2019, 25, 2185-2193.	3.2	41
52	Characterizing Spatial Lung Function for Esophageal Cancer Patients Undergoing Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 738-746.	0.4	9
53	Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreas cancer.. Journal of Clinical Oncology, 2019, 37, 370-370.	0.8	2
54	Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1203-1210.	2.3	14

#	ARTICLE	IF	CITATIONS
55	Radiation Therapy: The North American Approach. , 2019, , 365-403.		1
56	Impact of radiation dose during neoadjuvant chemoradiation on postoperative complications in esophageal (EC) and gastroesophageal junction cancers (GEJC).. Journal of Clinical Oncology, 2019, 37, 119-119.	0.8	0
57	Endoluminal high-dose-rate brachytherapy for locally recurrent or persistent esophageal cancer. Brachytherapy, 2018, 17, 621-627.	0.2	10
58	Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. Journal of Surgical Oncology, 2018, 117, 1073-1083.	0.8	19
59	Evaluation of respiratory motion-corrected cone-beam CT at end expiration in abdominal radiotherapy sites: a prospective study. Acta Oncologica, 2018, 57, 1017-1024.	0.8	7
60	Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity. Japanese Journal of Clinical Oncology, 2018, 48, 458-466.	0.6	31
61	Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. Advances in Radiation Oncology, 2018, 3, 34-41.	0.6	15
62	Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy for anal cancer. Quality of Life Research, 2018, 27, 97-103.	1.5	17
63	Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer, 2018, 18, 958.	1.1	38
64	Quality Control of Radiation Delivery for Lower Gastrointestinal Cancers. Current Treatment Options in Oncology, 2018, 19, 51.	1.3	3
65	The Role of Stereotactic Body Radiation Therapy in Pancreatic Cancer. Current Cancer Therapy Reviews, 2018, 14, 46-54.	0.2	0
66	Impact of lung and heart dose on survival after radiotherapy for esophageal cancer.. Journal of Clinical Oncology, 2018, 36, 3-3.	0.8	3
67	Radiation Therapy for Liver Metastases. , 2018, , 311-322.		0
68	Trans-intra-arterial gemcitabine versus continuation of IV gemcitabine and nab-paclitaxel following radiotherapy for locally advanced pancreatic cancer (TiGeR-PaC).. Journal of Clinical Oncology, 2018, 36, TPS529-TPS529.	0.8	0
69	Early outcomes in patients with locally advanced rectal cancer following total neoadjuvant therapy.. Journal of Clinical Oncology, 2018, 36, 848-848.	0.8	0
70	Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. Cancer, 2017, 123, 3402-3409.	2.0	29
71	An evaluation of motion mitigation techniques for pancreatic SBRT. Radiotherapy and Oncology, 2017, 124, 168-173.	0.3	45
72	Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1087-1095.	0.4	44

#	ARTICLE	IF	CITATIONS
73	Stereotactic Body Radiotherapy for Liver Metastases. <i>Seminars in Radiation Oncology</i> , 2017, 27, 240-246.	1.0	25
74	ACR Appropriateness Criteria® Resectable Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 109-117.	0.6	7
75	Single Nucleotide Polymorphism TGF β 1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 924-930.	0.4	10
76	Reply to Tumor localization may change the type of adjuvant treatment in gastric cancer. <i>Cancer</i> , 2017, 123, 4737-4738.	2.0	0
77	Neural network dose models for knowledge-based planning in pancreatic <sc>SBRT</sc>. <i>Medical Physics</i> , 2017, 44, 6148-6158.	1.6	52
78	Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. <i>Pancreas</i> , 2017, 46, 904-912.	0.5	12
79	A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. <i>Translational Oncology</i> , 2017, 10, 760-765.	1.7	33
80	Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. <i>Acta Oncologica</i> , 2017, 56, 1746-1753.	0.8	38
81	Robotically Assisted Laparoscopic Ovarian Transposition in Women with Lower Gastrointestinal Cancer Undergoing Pelvic Radiotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 251-256.	0.7	14
82	Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection*. <i>Acta Oncologica</i> , 2017, 56, 384-390.	0.8	24
83	Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: Analysis of the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 228-236.	2.0	34
84	The impact of young adult colorectal cancer: incidence and trends in Colorado. <i>Colorectal Cancer</i> , 2017, 6, 49-56.	0.8	9
85	Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4007-4007.	0.8	11
86	Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1-1.	0.8	44
87	Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities. <i>Chinese Clinical Oncology</i> , 2017, 6, 28-28.	0.4	8
88	Stereotactic Body Radiation Therapy for Liver Metastases: Radiation Therapy Planning. , 2017, , 229-238.		0
89	Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e194-e203.	1.8	126
90	Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 828-837.	0.6	6

#	ARTICLE	IF	CITATIONS
91	Intensity-modulated Radiation Therapy for Anal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 8-12.	0.6	57
92	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer, 2016, 122, 2083-2090.	2.0	30
93	Cancer and Fertility Program Improves Patient Satisfaction With Information Received. Journal of Clinical Oncology, 2016, 34, 1780-1786.	0.8	75
94	Definitive Chemoradiotherapy (‘‘Watch-and-Wait’’ Approach). Seminars in Radiation Oncology, 2016, 26, 205-210.	1.0	9
95	Are fiducial markers useful surrogates when using respiratory gating to reduce motion of gastroesophageal junction tumors?. Acta Oncologica, 2016, 55, 1040-1046.	0.8	8
96	Timing Is Everything: What Is the Optimal Duration After Chemoradiation for Surgery for Rectal Cancer?. Journal of Clinical Oncology, 2016, 34, 3724-3728.	0.8	6
97	Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Practical Radiation Oncology, 2016, 6, 417-424.	1.1	19
98	Clinical Use of a Novel Balloon Based Esophageal Brachytherapy Applicator. Brachytherapy, 2016, 15, S35.	0.2	0
99	Prospective Evaluation of Endoluminal High Dose Rate Brachytherapy with Concurrent Chemotherapy for Rectal or Anal Cancer Patients: Initial Clinical Results. Brachytherapy, 2016, 15, S142.	0.2	1
100	Acute toxicity with intensity modulated radiotherapy versus 3-dimensional conformal radiotherapy during preoperative chemoradiation for locally advanced rectal cancer. Radiotherapy and Oncology, 2016, 121, 252-257.	0.3	31
101	Distribution of FDG-avid nodes in esophageal cancer: implications for radiotherapy target delineation. Radiation Oncology, 2016, 11, 156.	1.2	11
102	Stereotactic Body Radiation Therapy for Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 290-295.	1.0	9
103	Treatment Selection and Survival Outcomes With and Without Radiation for Unresectable, Localized Intrahepatic Cholangiocarcinoma. Cancer Journal (Sudbury, Mass), 2016, 22, 237-242.	1.0	26
104	Kilovoltage Imaging of Implanted Fiducials to Monitor Intrafraction Motion With Abdominal Compression During Stereotactic Body Radiation Therapy for Gastrointestinal Tumors. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1042-1049.	0.4	13
105	Risk of second cancers in the era of modern radiation therapy: does the risk/benefit analysis overcome theoretical models?. Cancer and Metastasis Reviews, 2016, 35, 277-288.	2.7	35
106	Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. Practical Radiation Oncology, 2016, 6, 78-85.	1.1	30
107	Advances in the Management of Anal Cancer. Current Oncology Reports, 2016, 18, 20.	1.8	18
108	Optimize and refine therapeutic index in radiation therapy: Overview of a century. Cancer Treatment Reviews, 2016, 45, 58-67.	3.4	60

#	ARTICLE	IF	CITATIONS
109	Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. <i>European Radiology</i> , 2016, 26, 4303-4312.	2.3	63
110	Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. <i>Practical Radiation Oncology</i> , 2016, 6, 166-175.	1.1	26
111	Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. <i>Acta Oncologica</i> , 2016, 55, 208-216.	0.8	27
112	Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e194-e203.	1.8	16
113	Technical Note: Intrafractional changes in time lag relationship between anterior-posterior external and superior-inferior internal motion signals in abdominal tumor sites. <i>Medical Physics</i> , 2015, 42, 2813-2817.	1.6	0
114	ACR Appropriateness Criteria® Local Excision in Early Stage Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 520-525.	0.6	1
115	Refining the Role for Adjuvant Radiotherapy in Gastric Cancer: Risk Stratification Is Key. <i>Journal of Clinical Oncology</i> , 2015, 33, 3082-3084.	0.8	11
116	Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1658-1665.	2.9	15
117	Modeling Pancreatic Tumor Motion Using 4-Dimensional Computed Tomography and Surrogate Markers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 579-587.	0.4	31
118	Long-Term Survival After High-Dose-Rate Brachytherapy for Locally Advanced or Recurrent Colorectal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 2168-2178.	0.7	12
119	Prospective study of vaginal dilator use adherence and efficacy following radiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 116, 149-155.	0.3	66
120	FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3512-3521.	0.7	135
121	Dosimetric Predictors of Radiation-Induced Vaginal Stenosis After Pelvic Radiation Therapy for Rectal and Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 548-554.	0.4	43
122	Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. <i>Cancer</i> , 2015, 121, 1128-1137.	2.0	447
123	Design of a Novel Applicator for Esophageal High Dose Rate Brachytherapy. <i>Brachytherapy</i> , 2015, 14, S101-S102.	0.2	0
124	Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 1737-1744.	0.8	30
125	Pancreatic cancer and SBRT: A new potential option?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 377-384.	0.3	20
126	Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 53-9.	0.6	8

#	ARTICLE	IF	CITATIONS
127	Predicting complete response: is there a role for non-operative management of rectal cancer?. Journal of Gastrointestinal Oncology, 2015, 6, 241-6.	0.6	18
128	Automatic tracking of arbitrarily shaped implanted markers in kilovoltage projection images: A feasibility study. Medical Physics, 2014, 41, 071906.	1.6	22
129	Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. Radiotherapy and Oncology, 2014, 113, 29-34.	0.3	47
130	Rapid estimation of 4DCT motion artifact severity based on 1D breathing surrogate periodicity. Medical Physics, 2014, 41, 111717.	1.6	18
131	Image-guided Radiation Therapy for Liver Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 561-567.	0.6	6
132	The Effectiveness of a Pneumatic Compression Belt in Reducing Respiratory Motion of Abdominal Tumors in Patients Undergoing Stereotactic Body Radiotherapy. Technology in Cancer Research and Treatment, 2014, 13, 259-267.	0.8	39
133	Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial. Journal of Clinical Oncology, 2014, 32, 513-518.	0.8	375
134	Non-operative management of locally advanced rectal cancer. Seminars in Colon and Rectal Surgery, 2014, 25, 22-25.	0.2	1
135	A Retrospective Review of 126 High-Grade Neuroendocrine Carcinomas of the Colon and Rectum. Annals of Surgical Oncology, 2014, 21, 2956-2962.	0.7	123
136	Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment. Journal of the National Cancer Institute, 2014, 106, .	3.0	179
137	Physicians' Beliefs About the Benefits and Risks of Adjuvant Therapies for Stage II and Stage III Colorectal Cancer. Journal of Oncology Practice, 2014, 10, e360-e367.	2.5	9
138	Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers. Annals of Surgical Oncology, 2014, 21, 1130-1137.	0.7	29
139	Neoadjuvant Radiation Therapy Prior to Total Mesorectal Excision for Rectal Cancer is Not Associated with Postoperative Complications Using Current Techniques. Annals of Surgical Oncology, 2014, 21, 2295-2302.	0.7	14
140	Upper abdominal normal organ contouring guidelines and atlas: A Radiation Therapy Oncology Group consensus. Practical Radiation Oncology, 2014, 4, 82-89.	1.1	103
141	Performance of a Nomogram Predicting Disease-Specific Survival After an R0 Resection for Gastric Cancer in Patients Receiving Postoperative Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 88, 624-629.	0.4	13
142	Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 235-243.	2.3	14
143	Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 513-519.	2.3	186
144	ACR Appropriateness Criteria®-Anal Cancer. Gastrointestinal Cancer Research: GCR, 2014, 7, 4-14.	0.8	7

#	ARTICLE	IF	CITATIONS
145	Role of radiation therapy in the management of pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2013, 107, 86-96.	0.8	46
146	Is There a Role for Neoadjuvant Chemotherapy Without Radiotherapy in Locally Advanced Rectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 126-129.	1.0	0
147	Intraoperative high-dose-rate brachytherapy using dose painting technique: Evaluation of safety and preliminary clinical outcomes. <i>Brachytherapy</i> , 2013, 12, 1-7.	0.2	16
148	Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients. <i>Brachytherapy</i> , 2013, 12, 463-470.	0.2	22
149	Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: A propensity score analysis. <i>Radiotherapy and Oncology</i> , 2013, 107, 189-194.	0.3	41
150	Quality Research in Radiation Oncology Analysis of Clinical Performance Measures in the Management of Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 355-362.	0.4	5
151	Positron Emission Tomography Imaging for Gastroesophageal Junction Tumors. <i>Seminars in Radiation Oncology</i> , 2013, 23, 10-15.	1.0	19
152	Esophagogastric Junction Carcinoma: Introduction. <i>Seminars in Radiation Oncology</i> , 2013, 23, 1-2.	1.0	2
153	What is the Significance of the Circumferential Margin in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy?. <i>Annals of Surgical Oncology</i> , 2013, 20, 1179-1184.	0.7	66
154	Quality Assurance for Radiotherapy: A Priority for Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2013, 105, 376-377.	3.0	20
155	Does preoperative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase postoperative morbidity? A case-matched analysis. <i>Hpb</i> , 2013, 15, 574-580.	0.1	34
156	Multicentre results of stereotactic body radiotherapy for secondary liver tumours. <i>Hpb</i> , 2013, 15, 851-857.	0.1	28
157	A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 87-9.	0.8	1
158	Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 129-36.	0.8	13
159	Pulmonary Recurrence Predominates After Combined Modality Therapy for Rectal Cancer. <i>Annals of Surgery</i> , 2012, 256, 111-116.	2.1	63
160	Nonoperative Management of Rectal Cancer With Complete Clinical Response After Neoadjuvant Therapy. <i>Annals of Surgery</i> , 2012, 256, 965-972.	2.1	325
161	Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2012, 159, 329-339.	1.2	22
162	Comparison of Heart and Coronary Artery Doses Associated With Intensity-Modulated Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Distal Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1580-1586.	0.4	128

#	ARTICLE	IF	CITATIONS
163	Radiation Therapy Oncology Group Consensus Panel Guidelines for the Delineation of the Clinical Target Volume in the Postoperative Treatment of Pancreatic Head Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 901-908.	0.4	114
164	Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. <i>Acta Oncologica</i> , 2012, 51, 575-583.	0.8	102
165	ACR Appropriateness Criteria® Resectable Rectal Cancer. <i>Radiation Oncology</i> , 2012, 7, 161.	1.2	21
166	The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. <i>Journal of Surgical Oncology</i> , 2012, 106, 647-650.	0.8	25
167	Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. <i>Cancer</i> , 2012, 118, 5414-5423.	2.0	33
168	Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease. <i>Annals of Surgical Oncology</i> , 2012, 19, 1663-1669.	0.7	52
169	Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 67-67.	0.8	3
170	Patient versus clinician symptom reporting during chemoradiation for rectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 646-646.	0.8	3
171	Radiation in Rectal Cancer: What Are the Options and If/When Can It Be Avoided?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 219-221.	1.8	0
172	Patient-Reported Outcomes vs. Clinician Symptom Reporting During Chemoradiation for Rectal Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 119-24.	0.8	28
173	Management of a locally advanced rectal cancer in a patient who declined surgery. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 205-9.	0.8	0
174	Surgery and High-Dose-Rate Intraoperative Radiation Therapy for Recurrent Squamous-Cell Carcinoma of the Anal Canal. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 1090-1097.	0.7	29
175	What is the significance of circumferential margin in locally advanced rectal cancer after neoadjuvant chemoradiotherapy?. <i>Journal of the American College of Surgeons</i> , 2011, 213, S115.	0.2	0
176	Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. <i>Cancer</i> , 2011, 117, 3342-3351.	2.0	132
177	Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 181-188.	0.4	230
178	Dose-Escalation Study of Single-Fraction Stereotactic Body Radiotherapy for Liver Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 486-493.	0.4	279
179	Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. <i>Gynecologic Oncology</i> , 2010, 119, 237-242.	0.6	21
180	Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. <i>Cancer</i> , 2010, 116, 3943-3952.	2.0	76

#	ARTICLE	IF	CITATIONS
181	EUS-guided fiducial placement for image-guided radiation therapy in GI malignancies by using a 22-gauge needle (with). <i>Gastrointestinal Endoscopy</i> , 2010, 71, 1204-1210.	0.5	110
182	Correction of motion artifacts in cone-beam CT using a patient-specific respiratory motion model. <i>Medical Physics</i> , 2010, 37, 2901-2909.	1.6	97
183	Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. <i>Cancer</i> , 2009, 115, 665-672.	2.0	353
184	Sphincter Preservation in Low Rectal Cancer is Facilitated by Preoperative Chemoradiation and Intersphincteric Dissection. <i>Annals of Surgery</i> , 2009, 249, 236-242.	2.1	206
185	Pancreatic Tumor Motion on a Single Planning 4D-CT Does Not Correlate With Intrafraction Tumor Motion During Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 364-368.	0.6	92
186	From phase-based to displacement-based gating: a software tool to facilitate respiration-gated radiation treatment. <i>Journal of Applied Clinical Medical Physics</i> , 2009, 10, 132-141.	0.8	20
187	Successful Treatment of Esophageal Cancer with Airway Invasion with Induction Chemotherapy and Concurrent Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2009, 4, 432-434.	0.5	8
188	Predictive Value of Initial PET-SUVmax in Patients with Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2009, 4, 875-879.	0.5	80
189	Squamous-cell Carcinoma of the Anal Canal: Predictors of Treatment Outcome. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 147-153.	0.7	100
190	Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. <i>Cancer</i> , 2008, 113, 57-64.	2.0	228
191	Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 678-686.	0.4	308
192	Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5240-5247.	0.8	65
193	Impact of Integrated PET/CT on Variability of Target Volume Delineation in Rectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2007, 6, 31-36.	0.8	86
194	Intensity-modulated radiotherapy for lymphoma involving the mediastinum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 198-206.	0.4	96
195	Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 320-323.	0.4	308
196	Dosimetric analysis of a simplified intensity modulation technique for prone breast radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 95-102.	0.4	46
197	Intraoperative high-dose-rate brachytherapy for pediatric solid tumors: a 10-year experience. <i>Brachytherapy</i> , 2003, 2, 139-146.	0.2	36
198	Whole abdominopelvic radiotherapy for desmoplastic small round-cell tumor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 170-176.	0.4	68